Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.
July 13, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...
MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19
June 29, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces it has secured a $2 million in debt financing with Golden...